Weight Loss Drugs

Weight loss drugs have moved from a niche corner of medicine to one of the most closely watched stories in health and business. The current wave is led by GLP-1 medicines that mimic gut hormones to curb appetite and improve blood sugar control. These include semaglutide, the active ingredient in Ozempic and Wegovy. Originally developed for type 2 diabetes, these treatments have produced weight reductions large enough to reshape how doctors, insurers, and patients think about obesity.

Why it matters now

The field is shifting quickly on several fronts. Oral versions are beginning to move through regulatory review and reach patients, offering an alternative to weekly injections. A next generation of candidates is advancing through clinical trials with the promise of even greater effect. These include multi-hormone drugs such as retatrutide and combination therapies like CagriSema.

At the same time, pricing has become a political and economic flashpoint. List prices, negotiated government rates, and manufacturer deals have produced a confusing patchwork of costs for Medicare and commercial buyers.

The ripple effects extend well beyond pharmacies. Widespread use of these drugs is influencing food and restaurant businesses, insurer budgets, and investor expectations across the pharmaceutical sector.

What you'll find here

This hub tracks:

• Approvals and regulation in the US, Europe, and other markets
• Clinical trial results, from early-stage safety data to late-stage efficacy readouts
• Pricing and access, including Medicare coverage, negotiated deals, and broader drug-cost trends
• Competition among drugmakers racing to develop pills and next-generation therapies
• Economic and social impact on industries and consumer behavior

Check back for ongoing coverage as this fast-moving market evolves.